Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage

Marta Motolese, Federica Mastroiacovo, Milena Cannella, Domenico Bucci, Anderson Gaglione, Barbara Riozzi, Robert Lütjens, Sonia M. Poli, Sylvain Celanire, Valeria Bruno, Giuseppe Battaglia, Ferdinando Nicoletti

Research output: Contribution to journalArticle

Abstract

Background: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. Results: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. Conclusion: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest.

Original languageEnglish
Article number66
JournalMolecular Brain
Volume8
Issue number1
DOIs
Publication statusPublished - Oct 24 2015

Fingerprint

Metabotropic Glutamate Receptors
N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine
Neurons
Ischemia
Hippocampal CA1 Region
Pyramidal Cells
Brain Diseases
Drug Delivery Systems
Acetylation
Heart Arrest
Histones
Shock
Therapeutics
Down-Regulation
Ligands
Messenger RNA
metabotropic glutamate receptor 2

Keywords

  • ADX92639
  • Epigenetics
  • Global ischemia
  • mGlu2 receptors
  • Neuronal vulnerability

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Molecular Biology

Cite this

Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage. / Motolese, Marta; Mastroiacovo, Federica; Cannella, Milena; Bucci, Domenico; Gaglione, Anderson; Riozzi, Barbara; Lütjens, Robert; Poli, Sonia M.; Celanire, Sylvain; Bruno, Valeria; Battaglia, Giuseppe; Nicoletti, Ferdinando.

In: Molecular Brain, Vol. 8, No. 1, 66, 24.10.2015.

Research output: Contribution to journalArticle

@article{8ca4382c68ea4b9a8ccd1be57af80253,
title = "Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage",
abstract = "Background: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. Results: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. Conclusion: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest.",
keywords = "ADX92639, Epigenetics, Global ischemia, mGlu2 receptors, Neuronal vulnerability",
author = "Marta Motolese and Federica Mastroiacovo and Milena Cannella and Domenico Bucci and Anderson Gaglione and Barbara Riozzi and Robert L{\"u}tjens and Poli, {Sonia M.} and Sylvain Celanire and Valeria Bruno and Giuseppe Battaglia and Ferdinando Nicoletti",
year = "2015",
month = "10",
day = "24",
doi = "10.1186/s13041-015-0158-2",
language = "English",
volume = "8",
journal = "Molecular Brain",
issn = "1756-6606",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage

AU - Motolese, Marta

AU - Mastroiacovo, Federica

AU - Cannella, Milena

AU - Bucci, Domenico

AU - Gaglione, Anderson

AU - Riozzi, Barbara

AU - Lütjens, Robert

AU - Poli, Sonia M.

AU - Celanire, Sylvain

AU - Bruno, Valeria

AU - Battaglia, Giuseppe

AU - Nicoletti, Ferdinando

PY - 2015/10/24

Y1 - 2015/10/24

N2 - Background: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. Results: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. Conclusion: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest.

AB - Background: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. Results: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. Conclusion: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest.

KW - ADX92639

KW - Epigenetics

KW - Global ischemia

KW - mGlu2 receptors

KW - Neuronal vulnerability

UR - http://www.scopus.com/inward/record.url?scp=84945126888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945126888&partnerID=8YFLogxK

U2 - 10.1186/s13041-015-0158-2

DO - 10.1186/s13041-015-0158-2

M3 - Article

AN - SCOPUS:84945126888

VL - 8

JO - Molecular Brain

JF - Molecular Brain

SN - 1756-6606

IS - 1

M1 - 66

ER -